Pinocembrin demonstrated anticancer activity in breast cancer models by activating apoptosis, stopping the cell cycle, and inhibiting the PI3K/AKT signaling pathway in vivo and in vitro (58). The gene discussed is AKT1; the disease is breast cancer.